MCL Literature Feed

This case report describes the rare Warburg effect (severe hypoglycemia, lactic acidosis) in an MCL patient, highlighting its potential for cardiac toxicity and the utility of hemodialysis for stabilization.

This review, while focused on CLL, details the metabolic and toxicity profiles of covalent and non-covalent BTKis, informing MCL management strategies for adverse events and emerging resistance.

Severe neurotoxicity after brexucabtagene autoleucel is common, associated with MRI/EEG changes and longer hospitalization, but importantly does not negatively impact treatment response or survival in MCL patients.

This UK real-world study confirms bendamustine-rituximab toxicity rates are similar to clinical trials, identifying MCL histology and poor performance status as key risk factors for serious infections.

This retrospective study found 36% of ibrutinib-treated patients, including MCL, developed serious infections, with prior transplant and steroid use identifying a high-risk group needing potential prophylaxis.

In a mixed lymphoma cohort, this retrospective study found cardiac involvement in 1.5% of patients, primarily DLBCL with pericardial effusion, but provides no specific data on MCL.

This case report demonstrates that filgrastim-induced HLH in an MCL patient can be managed by switching to lenograstim with steroid prophylaxis, allowing continuation of intensive chemotherapy.

Ibrutinib plus venetoclax shows high efficacy (83% CR) and deep MRD negativity with good tolerability in Japanese patients with relapsed/refractory MCL, supporting its use in this population.

This Japanese post-marketing surveillance study confirms the real-world efficacy (59.9% ORR) and safety of ibrutinib in heavily pre-treated, elderly patients with relapsed/refractory MCL, supporting its routine use.

This Phase 1 study establishes the safety and recommended dose of a quadruplet regimen combining chemoimmunotherapy (BR) with dual targeted agents (ibrutinib, venetoclax) for relapsed/refractory MCL.

This study developed and validated a new lymphoma-specific patient-reported outcome measure using the EORTC Item Library, providing a crucial tool for assessing MCL symptoms in clinical trials.

Pirtobrutinib, a non-covalent BTKi, gained FDA accelerated approval for MCL after prior BTKi failure, offering a 50% overall response rate for this high-unmet-need population.

This review summarizes the evolution of MCL treatment, focusing on BTK inhibitor efficacy, toxicity, and their role in enabling personalized therapeutic strategies based on patient and disease factors.

Pirtobrutinib, the first approved non-covalent BTKi, offers a crucial new therapy for relapsed/refractory MCL by overcoming resistance mechanisms, including C481 mutations, from prior covalent BTK inhibitors.

The novel antiviral ensitrelvir resolved persistent COVID-19 in a heavily pretreated MCL patient on ibrutinib, highlighting a potential strategy to manage infections that delay essential lymphoma therapy.

An MCL patient with B-cell depletion had persistent COVID-19 for over 112 days, diagnosed via lower respiratory sampling, highlighting a unique vulnerability and successful treatment with convalescent plasma.

This review details the pathophysiology and management of CAR-T toxicities like CRS and ICANS, providing essential guidance for clinicians treating relapsed/refractory MCL patients with this therapy.

This review consolidates efficacy and toxicity data for FDA-approved CAR-T products in aggressive B-cell lymphomas, including MCL, serving as a practical guide for this established relapsed/refractory treatment.

This meta-analysis of 984 R/R MCL patients confirms high CAR-T efficacy (74% CR, 69% 1-year OS), providing robust, pooled outcome data for this heavily pretreated population.

This indirect comparison shows acalabrutinib has a superior safety profile to ibrutinib in relapsed/refractory MCL with similar efficacy, supporting its preferential use in this setting.

This case report identifies therapy-related acute myeloid leukemia as a serious long-term toxicity after brexucabtagene autoleucel, highlighting the need for post-CAR-T surveillance for secondary malignancies.

In a real-world cohort including MCL, the Hematotox-Score predicted early cytopenias post-CAR-T but not survival, underscoring the need for improved prognostic tools for toxicity management.

This phase 1 study established the safety and preliminary efficacy of a novel bortezomib, cladribine, and rituximab regimen for older, newly diagnosed mantle cell lymphoma patients.